Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/NEOSTEM-INC-13840447/news/NeoStem-Announces-First-Patient-Randomized-in-Pivotal-Phase-3-Melanoma-Immunotherapy-Clinical-Trial-20281179/?utm_source=whatsapp&utm_medium=social&utm_campaign=share